Agios’s Sarah Gheuens talks to In Vivo about the responsibility of providing new therapies to rare disease populations, building trust with historically underserved communities, and why she loves working with small molecules.
Sarah Gheuens, named as one of In Vivo’s Rising Leaders for 2022, leads the R&D department at rare disease company Agios Pharmaceuticals, Inc.
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Mikkel Wandahl Pederson, CEO and chief scientific officer at Commit Biologics, discussed the company’s mission to harness the powerful complement system for the treatment of serious diseases.
From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
